Literature DB >> 24395231

In vivo antibacterial activity of MRX-I, a new oxazolidinone.

Cong-Ran Li1, Qian-Qian Zhai, Xiu-Kun Wang, Xin-Xin Hu, Guo-Qing Li, Wei-Xin Zhang, Jing Pang, Xi Lu, Hong Yuan, Mikhail Fedorovich Gordeev, Le-Tian Chen, Xin-Yi Yang, Xue-Fu You.   

Abstract

MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), penicillin-intermediate S. pneumoniae (PISP), and vancomycin-resistant enterococci (VRE). In this study, the in vivo efficacy of orally administered MRX-I was evaluated using linezolid as a comparator. MRX-I showed the same or better efficacy than linezolid in both systemic and local infection models against the tested strains.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24395231      PMCID： PMC4023790          DOI： 10.1128/AAC.01526-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models.

Authors:  Noe Reyes; James B Aggen; Corwin F Kostrub
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  A simplified method of evaluating dose-effect experiments.

Authors:  J T LITCHFIELD; F WILCOXON
Journal:  J Pharmacol Exp Ther       Date:  1949-06       Impact factor: 4.030

3.  In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone.

Authors:  Cong-Ran Li; Yi Li; Guo-Qing Li; Xin-Yi Yang; Wei-Xin Zhang; Ren-Hui Lou; Jing-Fang Liu; Min Yuan; Philip Huang; Shan Cen; Li-Yan Yu; Li-Xun Zhao; Jian-Dong Jiang; Xue-Fu You
Journal:  J Antimicrob Chemother       Date:  2010-09-21       Impact factor: 5.790

4.  In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.

Authors:  Arnold Louie; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191
  4 in total
  11 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

3.  Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.

Authors:  Paul B Eckburg; Yigong Ge; Barry Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.

Authors:  Xiaojie Wu; Jian Meng; Hong Yuan; Dafang Zhong; Jicheng Yu; Guoying Cao; Xingdang Liu; Beining Guo; Yuancheng Chen; Yi Li; Yaoguo Shi; Mikhail F Gordeev; Jufang Wu; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

5.  Discovery of Antibacterial Contezolid Acefosamil: Innovative O-Acyl Phosphoramidate Prodrug for IV and Oral Therapies.

Authors:  Jinqian Liu; Wen Wang; Changqing Wang; Li Zhang; Xueliang Zhang; Shicong Liu; Yunhua Xu; Hailin Wang; Qing Dai; Chun Liu; Xinghai Wang; Zhengyu Yuan; Mikhail F Gordeev
Journal:  ACS Med Chem Lett       Date:  2022-06-29       Impact factor: 4.632

6.  Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections.

Authors:  Hong Yuan; Hailan Wu; Yingyuan Zhang; Haihui Huang; Yi Li; Junzhen Wu; Guoying Cao; Jicheng Yu; Beining Guo; Jufang Wu; Zhengyu Yuan; Yuancheng Chen; Wanqiu Yang; Xiaojie Wu; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2022-05-16       Impact factor: 5.938

Review 7.  Investigational drugs to treat methicillin-resistant Staphylococcus aureus.

Authors:  Cuong Vuong; Anthony J Yeh; Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Investig Drugs       Date:  2015-11-04       Impact factor: 6.206

8.  In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.

Authors:  Cecilia G Carvalhaes; Leonard R Duncan; Wen Wang; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 9.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

Review 10.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.